Replimune price target raised to $21 from $17 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA review process for RP1 in combination with Opdivo for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The clinical impact should readily bolster the approval case, the analyst tells investors in a research note.